The association between lung cancer (LC) and interstitial lung disease (ILD) can be
explained by the shared risk factors like smoking and physiopathology of fibrogenesis and …

Background The molecular profiling of patients with advanced non-small-cell lung cancer
(NSCLC) for known oncogenic drivers is recommended during routine care. Nationally …

Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Background: Prophylactic cranial irradiation in patients with small-cell lung cancer
decreases the overall rate of brain metastases without an effect on overall survival. It has …

In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in
centers that tested for ROS1 rearrangement. Eligible patients had stage IV lung …

Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are
driven by less common genomic alterations, registries provide complementary information …

Abstract Background and Aims The impact of diagnosis and treatment delays for non‐small
cell lung cancer management is poorly understood, even if the literature on the subject is …

Background HER2 mutations have been identified as oncogenic drivers in lung cancers and
are found in 1–2% of lung adenocarcinomas. There is, to date, no standard of care for these …

Background There is no recommended therapy for malignant pleural mesothelioma that has
progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control …

Background In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus
ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with …